Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.
MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...
CD5 immunohistochemistry (IHC) was performed on 404 DLBCLs to identify CD5 IHC+ and CD5 IHC– cases, which were subsequently characterized at the molecular level through mutational and transcriptional ...
A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the role of B cells and self-reactive antibodies in lupus, systemic sclerosis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results